PK of new molecules [Design Issues]

posted by nobody – 2017-04-18 16:19 (2558 d 21:35 ago) – Posting: # 17247
Views: 3,670

Hi!

What are we talking about? First-in-man? Mass balance? Dose-escalation in healthy volunteers?

If you have no experience (especially with the allometric scaling for first dose and necessary in vitro studies for tox/safety pharmacology/pk/metabolism) I would not even think about designing such trials based on "internet knowledge". Humans are not rats and rabbits.

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,656 registered users;
97 visitors (0 registered, 97 guests [including 3 identified bots]).
Forum time: 13:54 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5